190 related articles for article (PubMed ID: 20464572)
1. Effect of entacapone on plasma homocysteine levels in Parkinson's disease patients.
Nevrly M; Kanovsky P; Vranova H; Langova K; Hlustik P
Neurol Sci; 2010 Oct; 31(5):565-9. PubMed ID: 20464572
[TBL] [Abstract][Full Text] [Related]
2. Effects of vitamin B12, folate, and entacapone on homocysteine levels in levodopa-treated Parkinson's disease patients: A randomized controlled study.
Anamnart C; Kitjarak R
J Clin Neurosci; 2021 Jun; 88():226-231. PubMed ID: 33992189
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
Lyytinen J; Kaakkola S; Ahtila S; Tuomainen P; Teräväinen H
Mov Disord; 1997 Jul; 12(4):497-505. PubMed ID: 9251066
[TBL] [Abstract][Full Text] [Related]
4. Reduced plasma homocysteine levels in levodopa/entacapone treated Parkinson patients.
Valkovic P; Benetin J; Blazícek P; Valkovicová L; Gmitterová K; Kukumberg P
Parkinsonism Relat Disord; 2005 Jun; 11(4):253-6. PubMed ID: 15878587
[TBL] [Abstract][Full Text] [Related]
5. Effect of levodopa and entacapone treatment on plasma homocysteine levels in Parkinson's disease patients.
Nevrly M; Kanovsky P; Vranova H; Langova K; Hlustik P
Parkinsonism Relat Disord; 2009 Jul; 15(6):477-8. PubMed ID: 19028438
[No Abstract] [Full Text] [Related]
6. Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson's disease patients.
Lamberti P; Zoccolella S; Iliceto G; Armenise E; Fraddosio A; de Mari M; Livrea P
Mov Disord; 2005 Jan; 20(1):69-72. PubMed ID: 15390046
[TBL] [Abstract][Full Text] [Related]
7. Elevated homocysteine levels in levodopa-treated idiopathic Parkinson's disease: a meta-analysis.
Hu XW; Qin SM; Li D; Hu LF; Liu CF
Acta Neurol Scand; 2013 Aug; 128(2):73-82. PubMed ID: 23432663
[TBL] [Abstract][Full Text] [Related]
8. [Effects of entacapone on plasma homocysteine in Parkinson's disease patients on levodopa].
Zhao P; Yang JF; Liu W; Wang Y; Sun YN; Li Q; Zhang W; Zhang BS
Zhonghua Yi Xue Za Zhi; 2013 Feb; 93(7):512-5. PubMed ID: 23660319
[TBL] [Abstract][Full Text] [Related]
9. The effect of catechol-O-methyltransferase inhibition with entacapone on cardiovascular autonomic responses in L-Dopa-treated patients with Parkinson's disease.
Lyytinen J; Sovijärvi A; Kaakkola S; Gordin A; Teräväinen H
Clin Neuropharmacol; 2001; 24(1):50-7. PubMed ID: 11290882
[TBL] [Abstract][Full Text] [Related]
10. Endothelial dysfunction and hyperhomocysteinemia in Parkinson's disease: flow-mediated dilation study.
Yoon JH; Lee JS; Yong SW; Hong JM; Lee PH
Mov Disord; 2014 Oct; 29(12):1551-5. PubMed ID: 25154960
[TBL] [Abstract][Full Text] [Related]
11. Homocysteine Levels in Parkinson's Disease: Is Entacapone Effective?
Kocer B; Guven H; Comoglu SS
Biomed Res Int; 2016; 2016():7563705. PubMed ID: 27493964
[TBL] [Abstract][Full Text] [Related]
12. The effects of different repeated doses of entacapone on the pharmacokinetics of L-Dopa and on the clinical response to L-Dopa in Parkinson's disease.
Heikkinen H; Nutt JG; LeWitt PA; Koller WC; Gordin A
Clin Neuropharmacol; 2001; 24(3):150-7. PubMed ID: 11391126
[TBL] [Abstract][Full Text] [Related]
13. The influence of levodopa, entacapone and homocysteine on prevalence of polyneuropathy in patients with Parkinson's disease.
Grofik M; Sivák Š; Nosáľ V; Turčanová Koprušáková M; Michalik J; Čierny D; Tatarková Z; Kurča E
J Neurol Sci; 2018 Sep; 392():28-31. PubMed ID: 30097148
[No Abstract] [Full Text] [Related]
14. Plasma homocysteine levels in Parkinson's disease: role of antiparkinsonian medications.
Zoccolella S; Lamberti P; Armenise E; de Mari M; Lamberti SV; Mastronardi R; Fraddosio A; Iliceto G; Livrea P
Parkinsonism Relat Disord; 2005 Mar; 11(2):131-3. PubMed ID: 15734674
[TBL] [Abstract][Full Text] [Related]
15. Effects of One-Day Application of Levodopa/Carbidopa/Entacapone versus Levodopa/Carbidopa/Opicapone in Parkinson's Disease Patients.
Müller T; Schlegel E; Zingler S; Thiede HM
Cells; 2022 Apr; 11(9):. PubMed ID: 35563817
[TBL] [Abstract][Full Text] [Related]
16. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study.
Stocchi F; Rascol O; Kieburtz K; Poewe W; Jankovic J; Tolosa E; Barone P; Lang AE; Olanow CW
Ann Neurol; 2010 Jul; 68(1):18-27. PubMed ID: 20582993
[TBL] [Abstract][Full Text] [Related]
17. Entacapone: a catechol-O-methyltransferase inhibitor for the adjunctive treatment of Parkinson's disease.
Najib J
Clin Ther; 2001 Jun; 23(6):802-32; discussion 771. PubMed ID: 11440283
[TBL] [Abstract][Full Text] [Related]
18. The COMT Val158Met polymorphism affects the response to entacapone in Parkinson's disease: a randomized crossover clinical trial.
Corvol JC; Bonnet C; Charbonnier-Beaupel F; Bonnet AM; Fiévet MH; Bellanger A; Roze E; Meliksetyan G; Ben Djebara M; Hartmann A; Lacomblez L; Vrignaud C; Zahr N; Agid Y; Costentin J; Hulot JS; Vidailhet M
Ann Neurol; 2011 Jan; 69(1):111-8. PubMed ID: 21280081
[TBL] [Abstract][Full Text] [Related]
19. Entacapone in the treatment of Parkinson's disease.
Schrag A
Lancet Neurol; 2005 Jun; 4(6):366-70. PubMed ID: 15907741
[TBL] [Abstract][Full Text] [Related]
20. Bimodal administration of entacapone in Parkinson's disease patients improves motor control.
Bet L; Bareggi SR; Pacei F; Bondiolotti G; Meola G; Schapira AH
Eur J Neurol; 2008 Mar; 15(3):268-73. PubMed ID: 18290846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]